Clinical Trial Update: A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM) [Phase 2]

View source ↗

Summary

Withdrawal notice for a Phase 2 placebo-controlled proof-of-concept study evaluating 0.5% roflumilast cream in mild atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Roflumilast Cream (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Dermatitis | Phase 2 | Status: WITHDRAWN